Genocea Biosciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Genocea Biosciences sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Genocea Biosciences: 9 sponsored US clinical trials, none currently recruiting.

Genocea Biosciences sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Genital Herpes Simplex Type 2, with 3 trials.

Top-decile sponsor footprint

Genocea Biosciences ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

TERMINATED Phase 1

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

NCT04596033
COMPLETED Phase 1

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT03633110
TERMINATED Phase 2

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

NCT03146403
COMPLETED

Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity

NCT02910284
COMPLETED Phase 2

Evaluating New Formulation of Therapeutic HSV-2 Vaccine

NCT02515175
COMPLETED Phase 2

Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study

NCT02300142
COMPLETED Phase 2

Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine

NCT02114060
COMPLETED Phase 1

Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine

NCT01995617
COMPLETED Phase 1

Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine

NCT01667341

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 4

Therapeutic Areas

Genital Herpes Simplex Type 2 3

How the Genocea Biosciences early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 7 completed (78%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Genital Herpes Simplex Type 2 (3 trials), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Genocea Biosciences: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Genocea Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Genocea Biosciences4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Genocea Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Genocea Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Genocea Biosciences page

9 registered trials is a research-attention snapshot, not an endorsement of Genocea Biosciences or any single study.

  • None of Genocea Biosciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Genital Herpes Simplex Type 2 is the condition Genocea Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Genital Herpes Simplex Type 2 trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Genocea Biosciences pipeline card: 9 registered trials from official public datasets.Report a data error.